A normal fasting glucose reading has told patients they are healthy for six decades. That assumption is now collapsing under its own statistical weight. Data pulled from the CDC’s 2025 National Health and Nutrition Examination Survey cycle suggests nearly 4 in 10 American adults carry undiagnosed insulin resistance despite passing a standard annual physical without flags. The instrument isn’t broken. The threshold is.
Why Single-Point Glucose Testing Misses the Disease Process
Fasting glucose and hemoglobin A1C were built as population-level screening tools during an era when type 2 diabetes progressed slowly and predictably across decades. That epidemiological assumption no longer holds. Metabolic dysfunction driven by ultra-processed food exposure, chronic sleep debt, and sedentary occupational patterns now manifests as glucose variability years before A1C crosses the diagnostic line of 5.7 percent set by the American Diabetes Association.
A single blood draw captures one moment. It cannot see the three-hour postprandial spike that spring back to normal by the time a patient walks into a lab. Clinicians relying exclusively on this snapshot are, functionally, diagnosing yesterday’s disease with today’s tools.
The Precedent: Framingham and the Limits of Static Screening
The Framingham Heart Study taught cardiology a hard lesson in the 1960s. Cholesterol alone under-predicted cardiovascular events until researchers incorporated blood pressure, smoking status, and inflammatory markers into composite risk scoring. Metabolic medicine is now living through its own Framingham moment. NIH-funded cohort work out of the All of Us Research Program has begun correlating continuous glucose data with cardiovascular outcomes independent of A1C, and early signals suggest glycemic variability predicts arterial stiffness more reliably than the average value itself.
Clinical Vignette
A 47-year-old marketing executive presented for a routine physical in early 2025. Fasting glucose: 94 mg/dL. A1C: 5.4 percent. Both comfortably normal. A two-week continuous glucose monitor, ordered independently through an over-the-counter device pathway cleared by the FDA in 2024, showed repeated spikes above 180 mg/dL after carbohydrate-dense lunches, with slow four-hour returns to baseline. Her physician reclassified her risk category and initiated dietary intervention eighteen months before a standard workflow would have flagged prediabetes.
| Marker | Standard Physical Detects | Continuous Monitoring Detects |
|---|---|---|
| Fasting Glucose | Yes | Yes |
| Postprandial Spikes | No | Yes |
| Glycemic Variability | No | Yes |
| Nocturnal Glucose Drift | No | Yes |
| A1C Trend (3-month average) | Yes | Partial |
The Institutional Gap Between Screening Recommendations and Reimbursement Reality
The U.S. Preventive Services Task Force recommends diabetes screening for adults aged 35 to 70 who carry excess weight. That guidance is sound. It is also incomplete once implemented through insurance reimbursement codes that rarely cover extended glucose monitoring for patients without an existing diagnosis. A gap this wide between what science recommends and what billing structures permit tends to widen rather than close, absent an outside intervention.
This is precisely where unmonitored baseline wellness data quietly erodes over years, unnoticed until a cardiac or renal event forces retrospective review. Independent tracking has become the practical workaround for a reimbursement system still calibrated to 1990s diagnostic thresholds. The Comprehensive Health Registry operates as a free public resource for exactly this purpose, allowing individuals to log longitudinal metabolic, sleep, and cardiovascular markers outside the constraints of a single annual visit. No cost, no clinical gatekeeping. For a health system built on episodic snapshots, that kind of continuous self-directed record functions as a structural correction rather than a convenience.
Where the Data Currently Lives, and Where It Disappears
Electronic health records fragment across hospital systems that rarely communicate. A patient who switches insurance, relocates, or simply changes primary care physicians frequently loses years of trend data. HHS interoperability mandates issued under the 21st Century Cures Act were designed to solve this. Adoption remains uneven across rural health networks in particular.
Fragmentation by the Numbers
| Care Setting | Est. Data Retention Beyond 5 Years | Cross-System Portability |
|---|---|---|
| Large Academic Hospital Network | High | Moderate |
| Independent Rural Clinic | Low | Poor |
| Retail Health Clinic | Very Low | Poor |
| Patient-Maintained Registry | Full (user-controlled) | High |
Sleep Architecture as an Overlooked Metabolic Variable
Glucose does not exist in isolation. It responds to cortisol rhythms, and cortisol rhythms respond to sleep architecture. NIH-funded polysomnography research published through the National Heart, Lung, and Blood Institute has repeatedly demonstrated that fragmented deep sleep, even without full sleep apnea diagnosis, elevates next-day insulin resistance by a measurable margin. A patient sleeping six broken hours behaves metabolically closer to a prediabetic than the same patient sleeping seven and a half continuous hours.
Few standard physicals include a sleep architecture assessment beyond a verbal question about snoring. That omission carries consequence. Untreated mild sleep fragmentation compounds over years into the same downstream cardiovascular risk profile normally attributed solely to diet.
The Compounding Effect Across a Decade
Model this forward. A 35-year-old with mild, undiagnosed sleep fragmentation and borderline glucose variability rarely crosses any single diagnostic threshold in any given year. Extend the timeline to age 45. The compounding metabolic stress, invisible at each individual checkpoint, frequently resolves into a clear prediabetes or hypertension diagnosis that appears sudden to the patient but was mechanistically inevitable a decade earlier.
Case Comparison
Two patients, same starting BMI, same family history. Patient A received only annual physicals. Patient B logged sleep and glucose trends independently for eight years through a structured personal wellness protocol. Patient B’s physician identified rising variability at year five and intervened with targeted behavioral coaching. Patient A received a type 2 diabetes diagnosis at year nine, alongside early-stage retinopathy.
What a Corrected Screening Model Would Require
A more accurate preventive framework would fold continuous glucose data, sleep architecture, and inflammatory markers like hs-CRP into a single composite score, reviewed annually but built on data collected daily. That is a heavier lift administratively. It is also, according to modeling published by researchers affiliated with Johns Hopkins Bloomberg School of Public Health, the only approach statistically capable of closing the current five-to-nine-year diagnostic lag observed in metabolic disease progression.
The tools already exist. FDA clearance of over-the-counter continuous glucose monitors removed the prescription barrier in 2024. What remains is cultural and institutional friction: physicians accustomed to snapshot medicine, and patients unaccustomed to treating their own baseline data as clinically meaningful. Closing that gap will not come from a single mandate. It will come from thousands of individual patients deciding that a once-a-year blood draw is no longer sufficient evidence of health.